α-1b干扰素治疗慢性乙型肝炎的远期疗效探讨  

Study on the Long-term Effect of α-1b Interferon in Treatment of Chronic Hepatitis B

作　　者：李海荣[1] 王有莲[1] 李金霞[1] 

机构地区：[1]山西晋城煤业集团总医院,晋城市048006

出　　处：《中国医院用药评价与分析》2002年第4期222-223,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的 :探讨国产基因重组α -1b干扰素对慢性乙型肝炎的远期疗效。方法 :以30例同期条件相仿且未用干扰素等抗病毒药物治疗的慢性乙型肝炎患者作为对照 ,前瞻性研究晋城地区33例应用α -1b干扰素治疗慢性乙型肝炎患者的远期疗效 ,平均随访时间5 2年。结果 :(1)治疗组总有效率75 7 % ,血清HBeAg、HBV -DNA转阴率分别为84 8 %、84 4 % ,对照组HBeAg、HBV -DNA转阴率分别为63 3 %、54 2 % ,两组比较有显著性差异 (P<0 05) ;(2)α -1b干扰素治疗后1、2、5、8、10年HBeAg转阴率相应为51 5 %、48 5 %、69 6 %、84 8 %、87 % ,HBV -DNA转阴率相应为53 5 %、48 5 %、84 4 %、86 6 %和86 6 % ,显示在随访期内 ,由于α -1b干扰素的远期持续效应 ,患者的HBV标志转阴率随时间的增加而呈上升趋势 ;(3)治疗组肝纤维化发生率低于对照组。结论 :国产α -1b干扰素对慢性乙型肝炎患者具有良好的远期抗HBV持续效应。OBJECTIVE:To study the long-term therapetuic effect of domestic recombination α-1b interferon on chronic hepatitis B.METHODS:In a prospective study,taking chronic hepatitis B patients without receiving interferon as control,we observed the long-term efficacy of α-1b interferon in treatment of 33 cases of chronic hepatitis B with an average follow-up period of 5.2 years.RESULTS:(1)In interferon group,the total effective rate and serum HBeAg,HBV-DNA negative-turn rates were 75.7%?84.8% and 84.4%;in control group,the serum HBeAg,HBV-DNA negative-turn rates were 63.3% and 54.2%,respectively.There were significant differences between two groups(P<0.05).(2)After 1?2?5?8 and 10 years treatment,the corresponding negative-turn rates of HBeAg were 51.5%?48.5%?69.6%?84.8% and 87% and the negative-turn rates of HBV-DNA were 52.5%?48.5%?84.4%?86.6% and 86.6% respectively.The results indicated that in follow-up period,the negative-turn rates of HBV markers increased with time because of the long-term sustained action of α-1b interferon.(3)The incidence of liver fibrosis was lower in interferon group than that in control group.CONCLUSION:Domestic α-1b interferon has long-term sustained anti-HBV effect on chronic hepatitis B and can improve the prognosis and potentially prevent liver fibrosis in hepatitis patients.

关 键 词：Α-1B干扰素 基因治疗 慢性乙型肝炎 远期疗效 抗病毒药物 

分 类 号：R512.62[医药卫生—内科学] R978[医药卫生—临床医学]